Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 79-83 , April 2002

Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview

  • Richard R.P. Warner

      Affiliations

    • Division of Gastroenterology, Department of Medicine, The Mount Sinai School of Medicine, New York, NY USA
    • Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, New York, NY USA
    • Division of Endocrinology and Metabolism, Department of Medicine, University of Iowa Health Center, Iowa City, IA USA
    • Corresponding Author InformationAddress reprint requests to Richard R.P. Warner, MD, 1751 York Ave, New York, NY 10128.
    • ,
  • Thomas M. O'Dorisio

      Affiliations

    • Division of Gastroenterology, Department of Medicine, The Mount Sinai School of Medicine, New York, NY USA
    • Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, New York, NY USA
    • Division of Endocrinology and Metabolism, Department of Medicine, University of Iowa Health Center, Iowa City, IA USA

References 

  1. Boerman OC, Oyen WJG, Corstens FHM. Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals. Semin Nucl Med. 2000;30:195–208
  2. Jenkins SA, Kynaston HG, Davies ND, et al. Somatostatin analogs in oncology: A look to the future. Chemotherapy. 2001;47(suppl 2):162–196
  3. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: An overview. Chemotherapy. 2001;47(suppl 2):1–29
  4. Slooter GD, Mearadji A, Breeman WA, et al. Somatostatin receptor imaging, therapy and new strategies in pa-tients with neuroendocrine tumors. Br J Surg. 2001;88:31–40
  5. Benali N, Ferjoux G, Puente E, et al. Somatostatin receptors. Digestion. 2000;62(suppl 1):27–32
  6. Tofani A, Cucchi R, Pompili A, et al. 111In-octreotide scintigraphy in pituitary adenomas. Q J Nucl Med. 1995;39(4 suppl 1):94–97
  7. Boni G, Ferdeghini M, Bellina CR, et al. [111In-DTPA-D-Phe]-Octreotide scintigraphy in functioning and nonfunctioning pituitary adenomas. Q J Nucl Med. 1995;39(4 suppl 1):90–93
  8. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713
  9. Jensen RT, Gibril F, Termanini B. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Yale J Biol Med. 1997;70:481–500
  10. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localization on management in patients with gastrinoma. J Nucl Med. 1999;40:539–553
  11. Jensen RT. Editorial: Somatostatin receptor-based scintigraphy and anti-tumor treatment—An expanding vista?. J Clin Endocrinol Metab. 2000;85:3507–3508
  12. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med. 1993;20:716–731
  13. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224–232
  14. Virgolini I, Traub T, Leimer M, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med. 2000;44:50–58
  15. Thakur ML, Marcus CS, Saeed S, et al. 99mTc-labeled vasoactive intestinal peptides analog for rapid localization of tumors in humans. J Nucl Med. 2000;41:107–110
  16. Jensen RT. Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization and treatment. Curr Opin Oncol. 2000;12:368–377
  17. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902
  18. Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: A prospective study. J Nucl Med. 2000;41:1646–1656
  19. Eriksson B, Bergstrom M, Orlefors H, et al. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med. 2000;44:68–76
  20. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373–380
  21. Soresi E, Bombardieri E, Chiti A, et al. Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabeled somatostatin analog in small-cell lung cancer. Tumori. 1995;81:125–127
  22. Kalkner KM, Janson ET, Nilsson S, et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers. Cancer Res. 1995;55(suppl 23):5801s–5804s
  23. O'Byrne KJ, Schally AV, Thomas A, et al. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy. 2001;47(suppl 2):78–108
  24. Rogers BE, Zinn KR, Buchsbaum DJ. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q J Nucl Med. 2000;44:208–223
  25. Frilling A, Malago M, Martin H, et al. Uses of somatostatin receptor scintigraphy to image extra-hepatic metastases of neuroendocrine tumors. Surgery. 1998;124:1000–1004
  26. Schirmer WJ, O'Dorisio TM, Schirmer TP, et al. Intraoperative localization of neuroendocrine tumors with I125-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery. 1993;114:745–752
  27. Benevento A, Dominioni L, Carcano G, et al. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe. Semin Surg Oncol. 1998;15:239–244
  28. Adama S, Baum RP. Intraoperative use of gamma-detecting probes for localized neuroendocrine tumors. Q J Nucl Med. 2000;44:59–67
  29. Cuntz MC, Levine EA, O'Dorisio TM, et al. Intraoperative gamma detection of 125I-lanreotide in women with primary breast cancer. Ann Surg Oncol. 1999;6:367–372
  30. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol. 1999;141:1–14
  31. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000;7:971–994
  32. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116–1121

PII: S0001-2998(02)80025-3

doi: 10.1053/snuc.2002.31020

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 79-83 , April 2002

Article Tools